GSK will buy Canadian-based biopharmaceutical company Bellus Health, investing $2 billion. The acquisition will give the U.K.-based pharmaceuticals company access to a cough medicine for the treatment of chronic cough (RCC for short). The drug is currently in Phase III clinical development with anticipated approval and...
